CA2569197A1 - Method of quickly detecting and/or assaying antigen by fluorescence correlation spectrometry - Google Patents
Method of quickly detecting and/or assaying antigen by fluorescence correlation spectrometry Download PDFInfo
- Publication number
- CA2569197A1 CA2569197A1 CA002569197A CA2569197A CA2569197A1 CA 2569197 A1 CA2569197 A1 CA 2569197A1 CA 002569197 A CA002569197 A CA 002569197A CA 2569197 A CA2569197 A CA 2569197A CA 2569197 A1 CA2569197 A1 CA 2569197A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- fluorescence
- labeled
- antibody
- correlation spectroscopy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Abstract
It is intended to provide a detection and/or assay method whereby an abnormal prion or an antigen, for example, an antigenic protein such as a harmful protein contained in a food material can be quickly and accurately detected and/or assayed by a convenient procedure. In detecting or assaying an antigen molecule by using the fluorescence correlation spectrometry (FCS), a fluorescence-labeled antibody fragment and a non-fluorescence-labeled complete antibody capable of binding to the fluorescence-labeled antibody fragment via an antigen are employed. Thus, a significant difference in diffusion speed arises between the fluorescence-labeled antibody fragment not bonded to the antigen and a complex formed by the antigen/antibody reaction among the fluorescence-labeled antibody fragment, the antigen and the non-fluorescence-labeled complete antibody. According to this method, an antigen can be detected and assayed by using FCS, even in the case of an antigen with a relatively low molecular weight such as an antigenic protein, independently from the shape or molecular weight of the antigen and thus antigens over a wide scope can be quickly assayed.
Description
DESCRIPTION
TITLE OF THE INVENTION
METHOD OF QUICKLY DETECTING AND/OR ASSAYING ANTIGEN BY
FLUORESCENCE CORRELATION SPECTROMETRY
Technical Field [0001]
The present invention relates to a method of quickly detecting and/or assaying an antigen, whereby an antigen such as an antigenic protein, for example, a pathogenic protein ( e. g., an abnormal prion) or a harmful protein contained in a food material is detected and/or assayed quickly by using fluorescence correlation spectroscopy.
Background Art [0002]
In the use of natural product-derived food materials or feed materials, the presence of a harmful protein, a pathogenic protein, or the like contained in those materials has raised a concern in recent years. Examples of harmful proteins include a controversial allergen protein contained in food materials such as buckwheat, wheat, and rice. Examples of pathogenic proteins include a pathogenic protein such as a controversial abnormal prion (infectious) contained in materials for edible meat and meat-and-bone meal. To explain it by illustration, an abnormal prion taken as a representative example of a pathogenic protein of concern in recent years is a protein that causes prion disease typified by bovine spongiform encephalopathy(BSE). A normal prion protein commonly present in animal brain and neural cell membrane surface is a glycoprotein with a molecular weight of approximately thirty-three thousands to thirty-five thousands(33to35kDa), and its infectious prion protein form is intracellularly accumulated in the brain (Lait, 76: 571-578, 1996). Abnormal prions, after entering into an animal body, convert normal prions produced at particular sites in the body into abnormal prions, resulting in the accumulation of the abnormal prions at those particular sites. The accumulation of the abnormal prions in the brain renders the brain spongiform, leading to animal death.
TITLE OF THE INVENTION
METHOD OF QUICKLY DETECTING AND/OR ASSAYING ANTIGEN BY
FLUORESCENCE CORRELATION SPECTROMETRY
Technical Field [0001]
The present invention relates to a method of quickly detecting and/or assaying an antigen, whereby an antigen such as an antigenic protein, for example, a pathogenic protein ( e. g., an abnormal prion) or a harmful protein contained in a food material is detected and/or assayed quickly by using fluorescence correlation spectroscopy.
Background Art [0002]
In the use of natural product-derived food materials or feed materials, the presence of a harmful protein, a pathogenic protein, or the like contained in those materials has raised a concern in recent years. Examples of harmful proteins include a controversial allergen protein contained in food materials such as buckwheat, wheat, and rice. Examples of pathogenic proteins include a pathogenic protein such as a controversial abnormal prion (infectious) contained in materials for edible meat and meat-and-bone meal. To explain it by illustration, an abnormal prion taken as a representative example of a pathogenic protein of concern in recent years is a protein that causes prion disease typified by bovine spongiform encephalopathy(BSE). A normal prion protein commonly present in animal brain and neural cell membrane surface is a glycoprotein with a molecular weight of approximately thirty-three thousands to thirty-five thousands(33to35kDa), and its infectious prion protein form is intracellularly accumulated in the brain (Lait, 76: 571-578, 1996). Abnormal prions, after entering into an animal body, convert normal prions produced at particular sites in the body into abnormal prions, resulting in the accumulation of the abnormal prions at those particular sites. The accumulation of the abnormal prions in the brain renders the brain spongiform, leading to animal death.
[0003]
The use of such food materials or feed materials requires detecting and assaying a harmful protein (e.g., an allergen protein) or a pathogenic protein contained in food materials or feed materials and avoiding the use of those containing harmful proteins or pathogenic proteins, for preventing humans or animals from ingesting harmful proteins ( e. g., an allergen protein) or pathogenic proteins contained in those materials.
The use of such food materials or feed materials requires detecting and assaying a harmful protein (e.g., an allergen protein) or a pathogenic protein contained in food materials or feed materials and avoiding the use of those containing harmful proteins or pathogenic proteins, for preventing humans or animals from ingesting harmful proteins ( e. g., an allergen protein) or pathogenic proteins contained in those materials.
[0004]
Immunoassay such as ELISA (enzyme-linked immunosorbent assay) or western blotting ( immunoblotting ) has heretofore been used in the assay of natural biological proteins such as a prion (abnormal). ELISA is a method performed on a solid phase, whereby an antigen or an antibody is labeled with an enzyme, and the presence of the antibody or the antigen is detected by use of the enzyme activity. ELISA is performed, for example, by a procedure of binding aMab 3F4 antibody to a prion immobilized on a microtiter plate and detecting this antibody with a second antibody that catalyzes coloring reaction by an enzyme coupled to the antibody (U.S. Patent No. 4806627). Alternatively, western blotting is a method whereby.a protein separated by electrophoresis is immobilized on a hydrophobic membrane, and the protein of interest is detected with an antigen-specific antibody. The detection of a prion by western blotting is performed, for example, by a procedure of detecting an abnormal prion by performing western blotting using a monoclonal anti-prion protein antibody Mab 13A5 (J. Infect. Dis. 154:
518-521, 1986).
Immunoassay such as ELISA (enzyme-linked immunosorbent assay) or western blotting ( immunoblotting ) has heretofore been used in the assay of natural biological proteins such as a prion (abnormal). ELISA is a method performed on a solid phase, whereby an antigen or an antibody is labeled with an enzyme, and the presence of the antibody or the antigen is detected by use of the enzyme activity. ELISA is performed, for example, by a procedure of binding aMab 3F4 antibody to a prion immobilized on a microtiter plate and detecting this antibody with a second antibody that catalyzes coloring reaction by an enzyme coupled to the antibody (U.S. Patent No. 4806627). Alternatively, western blotting is a method whereby.a protein separated by electrophoresis is immobilized on a hydrophobic membrane, and the protein of interest is detected with an antigen-specific antibody. The detection of a prion by western blotting is performed, for example, by a procedure of detecting an abnormal prion by performing western blotting using a monoclonal anti-prion protein antibody Mab 13A5 (J. Infect. Dis. 154:
518-521, 1986).
[0005]
However, to perform detection and assay of a prion by a conventional method, for example, ELISA or western blotting, the conventional method involves initially performing, for example, a procedure of digesting and removing in advance a normal prion from a test sample by treatment with proteinase K, for detecting an abnormal prion separately from a normal prion. Western blotting requires performing electrophoresis.
Moreover, this method involves complexities and takes much time.
Therefore, it presents a problem of being unsuitable for practicing a test on a large number of samples in a short time.
Furthermore, for achieving necessary sensitivity, ELISA
requires subjecting a sample after proteinase K treatment to denaturation treatment with guanidine thiocyanate and performing primary denaturation treatment with SDS and a protein concentration procedure by methanol treatment before the deaggregation of the prion protein, and also requires performing centrifugation both before the methanol treatment and before the treatment with guanidine thiocyanate. This centrifugation procedure takes much time. The method must perform such complicated treatment and therefore presents a problem of being unsuitable for practicing a test on a large number of samples in a short time.
However, to perform detection and assay of a prion by a conventional method, for example, ELISA or western blotting, the conventional method involves initially performing, for example, a procedure of digesting and removing in advance a normal prion from a test sample by treatment with proteinase K, for detecting an abnormal prion separately from a normal prion. Western blotting requires performing electrophoresis.
Moreover, this method involves complexities and takes much time.
Therefore, it presents a problem of being unsuitable for practicing a test on a large number of samples in a short time.
Furthermore, for achieving necessary sensitivity, ELISA
requires subjecting a sample after proteinase K treatment to denaturation treatment with guanidine thiocyanate and performing primary denaturation treatment with SDS and a protein concentration procedure by methanol treatment before the deaggregation of the prion protein, and also requires performing centrifugation both before the methanol treatment and before the treatment with guanidine thiocyanate. This centrifugation procedure takes much time. The method must perform such complicated treatment and therefore presents a problem of being unsuitable for practicing a test on a large number of samples in a short time.
[0006]
Thus, to improve the problems of ELISA or western blotting used in the detection and assay of a prion, some methods have been proposed recently. For example, Japanese Laid-Open Patent Application No. 10-267928 has disclosed an immuno-PCR method that applies ELISA in detecting an abnormal prion protein with high sensitivity, whereby an anti-prion protein antibody is used and labeled with an arbitrary DNA fragment, which is in turn detected by PCR. Further, Japanese Laid-Open Patent Application No. 2003-130880 has disclosed a method of immunoassaying an abnormal prion with high sensitivity without performing a time-consuming electrophoresis or centrifugation procedure of the conventional ELISA or western blotting method.
In this method, a first antibody performing antigen/antibody reaction with an abnormal prion treated with a denaturing agent, or an antigen-binding fragment thereof is immobilized on magnetic particles and used as an immunoassay reagent for an abnormal prion to thereby assay the abnormal prion without performing the centrifugation procedure or electrophoresis of ELISA or western blotting. As a result, the method enabled a large number of samples to be tested in a short time is disclosed.
Thus, to improve the problems of ELISA or western blotting used in the detection and assay of a prion, some methods have been proposed recently. For example, Japanese Laid-Open Patent Application No. 10-267928 has disclosed an immuno-PCR method that applies ELISA in detecting an abnormal prion protein with high sensitivity, whereby an anti-prion protein antibody is used and labeled with an arbitrary DNA fragment, which is in turn detected by PCR. Further, Japanese Laid-Open Patent Application No. 2003-130880 has disclosed a method of immunoassaying an abnormal prion with high sensitivity without performing a time-consuming electrophoresis or centrifugation procedure of the conventional ELISA or western blotting method.
In this method, a first antibody performing antigen/antibody reaction with an abnormal prion treated with a denaturing agent, or an antigen-binding fragment thereof is immobilized on magnetic particles and used as an immunoassay reagent for an abnormal prion to thereby assay the abnormal prion without performing the centrifugation procedure or electrophoresis of ELISA or western blotting. As a result, the method enabled a large number of samples to be tested in a short time is disclosed.
[0007]
Furthermore, Japanese Laid-Open Patent Application No.
2003-215131 has disclosed a method of analyzing a prion protein by using a mass spectrum, whereby a prion protein in a body fluid sample is allowed to form a covalent bond by reaction with a chemical and thereby chemically modified, and in the presence of a pathogenic prion, at least additional one peak is observed in the mass spectrum. These methods are modifications of the conventional ELISA or western blotting method and however, still must undergo a variety of treatments.
Thus, these methods are not necessarily sufficient for conveniently and quickly detecting and assaying an antigenic protein such as a prion. Moreover, these detection and assay methods are less-than-suitable methods for automatically or semi-automatically performing treatment steps for detection and assay, and assaying large amounts of samples.
Furthermore, Japanese Laid-Open Patent Application No.
2003-215131 has disclosed a method of analyzing a prion protein by using a mass spectrum, whereby a prion protein in a body fluid sample is allowed to form a covalent bond by reaction with a chemical and thereby chemically modified, and in the presence of a pathogenic prion, at least additional one peak is observed in the mass spectrum. These methods are modifications of the conventional ELISA or western blotting method and however, still must undergo a variety of treatments.
Thus, these methods are not necessarily sufficient for conveniently and quickly detecting and assaying an antigenic protein such as a prion. Moreover, these detection and assay methods are less-than-suitable methods for automatically or semi-automatically performing treatment steps for detection and assay, and assaying large amounts of samples.
[0008]
On the other hand, fluorescence correlation spectroscopy ( FCS ) has been known in recent years as an analysis method that is frequently used particularly in the analysis and the like of molecules derived from organisms and can detect and assay, in almost realtime,the physical parameters of protein molecules such as number, sizes, or shapes without undergoing a step of physically separating a sample (Chem. Phys., 4, 390-401, 1974;
Biopolymers, 13, 1-27, 1974; Physical Rev. A, 10: 1938-1945, 1974; in Topics in Fluorescence Spectroscopy, 1, pp. 337-378, Plenum Press, New York and London, 1991; and R. Rigler, E. S.
Elson (Eds.), Fluorescence Correlation Spectroscopy. Theory and Applications, Springer, Berlin, 2001). FCS is practiced by capturing, within an exceedingly small region, the Brownian motions of fluorescence-labeled target molecules in a medium by a laser confocal scanning microscope system and thereby analyzing the diffusion time from the fluctuation of fluorescence intensity and assaying the physical parameters of the target molecules (the number and sizes of the molecules ).
Analysis by such FCS, which captures molecular fluctuation within a exceedingly small region, serves as an effective means in specif ically detecting intermolecular interaction with high sensitivity.
On the other hand, fluorescence correlation spectroscopy ( FCS ) has been known in recent years as an analysis method that is frequently used particularly in the analysis and the like of molecules derived from organisms and can detect and assay, in almost realtime,the physical parameters of protein molecules such as number, sizes, or shapes without undergoing a step of physically separating a sample (Chem. Phys., 4, 390-401, 1974;
Biopolymers, 13, 1-27, 1974; Physical Rev. A, 10: 1938-1945, 1974; in Topics in Fluorescence Spectroscopy, 1, pp. 337-378, Plenum Press, New York and London, 1991; and R. Rigler, E. S.
Elson (Eds.), Fluorescence Correlation Spectroscopy. Theory and Applications, Springer, Berlin, 2001). FCS is practiced by capturing, within an exceedingly small region, the Brownian motions of fluorescence-labeled target molecules in a medium by a laser confocal scanning microscope system and thereby analyzing the diffusion time from the fluctuation of fluorescence intensity and assaying the physical parameters of the target molecules (the number and sizes of the molecules ).
Analysis by such FCS, which captures molecular fluctuation within a exceedingly small region, serves as an effective means in specif ically detecting intermolecular interaction with high sensitivity.
[0009]
The feature of FCS used in the detection and assay of a protein or the like contained in a biological sample is that the concentrations or intermolecular interactions of fluorescence-labeled target molecules contained in a solution can be monitored in almost real time without undergoing a physical separation step. Therefore, a detection system using FCS can avoid a complicated Bound/Free separation step necessary for conventional analysis means (e.g., ELISA) predominantly used in biomolecule detection systems. Thus, this technique can assay large amounts of samples with high sensitivity in a short time and is also suitable for automatic assay.
The feature of FCS used in the detection and assay of a protein or the like contained in a biological sample is that the concentrations or intermolecular interactions of fluorescence-labeled target molecules contained in a solution can be monitored in almost real time without undergoing a physical separation step. Therefore, a detection system using FCS can avoid a complicated Bound/Free separation step necessary for conventional analysis means (e.g., ELISA) predominantly used in biomolecule detection systems. Thus, this technique can assay large amounts of samples with high sensitivity in a short time and is also suitable for automatic assay.
[0010]
To detect an antigenic protein or the like by using FCS, a fluorescence-labeled antibody molecule is used, and antigen/antibody reaction between the fluorescence-labeled antibody and the antigenic protein is utilized. Analysis is performed by utilizing a difference in diffusion rate depending on the shapes and molecular weights of the fluorescence-labeled antibody and an antigen/antibody complex molecule formed by the antigen/antibody reaction of the fluorescence-labeled antibody and the antigenic protein. In this context, the diffusion rate ( diffusion constant or D) refers to an area where molecules are freely diffused per unit time. On the other hand, the diffusion time (DT or TD) refers to time required for molecules to pass through a focal region determined depending on an apparatus.
To detect an antigenic protein or the like by using FCS, a fluorescence-labeled antibody molecule is used, and antigen/antibody reaction between the fluorescence-labeled antibody and the antigenic protein is utilized. Analysis is performed by utilizing a difference in diffusion rate depending on the shapes and molecular weights of the fluorescence-labeled antibody and an antigen/antibody complex molecule formed by the antigen/antibody reaction of the fluorescence-labeled antibody and the antigenic protein. In this context, the diffusion rate ( diffusion constant or D) refers to an area where molecules are freely diffused per unit time. On the other hand, the diffusion time (DT or TD) refers to time required for molecules to pass through a focal region determined depending on an apparatus.
[0011]
Thus, the accurate assay of an antigenic protein or the like in a sample by FCS requires using a combination of an antigen and an antibody that allows a significant difference to arise between the diffusion rate of the labeled antibody and the diffusion rate of an antigen/antibody complex formed by the antigen/antibody reaction of the labeled antibody and the antigenic protein. Thus, FCS could previously detect only the exceedingly limited type of an antigenic protein or the like due to this requirement. Conventional means for solving this problem comprised applying a variety of modifications to an antigen/antibody complex in consideration of the shapes and molecular weights of the antigen and the antibody and providing a significant difference in diffusion rate (Japanese Laid-Open Patent Application No. 2001-272404 and Japanese Patent No.
3517241) . However, even if these methods were used, there were limitations on an object to be detected to which the detection method by FCS was applicable.
Thus, the accurate assay of an antigenic protein or the like in a sample by FCS requires using a combination of an antigen and an antibody that allows a significant difference to arise between the diffusion rate of the labeled antibody and the diffusion rate of an antigen/antibody complex formed by the antigen/antibody reaction of the labeled antibody and the antigenic protein. Thus, FCS could previously detect only the exceedingly limited type of an antigenic protein or the like due to this requirement. Conventional means for solving this problem comprised applying a variety of modifications to an antigen/antibody complex in consideration of the shapes and molecular weights of the antigen and the antibody and providing a significant difference in diffusion rate (Japanese Laid-Open Patent Application No. 2001-272404 and Japanese Patent No.
3517241) . However, even if these methods were used, there were limitations on an object to be detected to which the detection method by FCS was applicable.
[0012]
Patent Document 1: Japanese Laid-Open Patent Application No.
Patent Document 2: Japanese Laid-Open Patent Application No.
Patent Document 3: Japanese Laid-Open Patent Application No.
Patent Document 4: Japanese Laid-Open Patent Application No.
Patent Document 5: Japanese Patent No. 3517241 Non-Patent Document 1: J. Infect. Dis. 154: 518-521, 1986 Non-Patent Document 2: Chem. Phys., 4, 390-401, 1974 Non-Patent Document 3: Biopolymers, 13, 1-27, 1974 , . ~
Non-Patent Document 4: Physical Rev. A, 10: 1938-1945, 1974 Non-Patent Document 5: in Topics in Fluorescence Spectroscopy, 1, pp. 337-378, Plenum Press, New York and London, 1991 Non-Patent Document 6: R. Rigler, E. S. Elson (Eds.), Fluorescence Correlation Spectroscopy, Theory and Applications, Springer, Berlin, 2001 Disclosure of the Invention Object to be solved by the Invention [0013]
An object of the present invention is to provide a method of quickly detecting and/or assaying an antigen, which can be applied widely to the detection and/or assay of an antigen such as an antigenic protein,for example,a pathogenic protein(e.g., an abnormal prion) or a harmful protein contained in a food material, whereby the antigen can be detected and/or assayed quickly and accurately by a convenient procedure.
Means to solve the object [0014]
During diligent studies to attain the above object, the present inventors have paid attention to fluorescence correlation spectroscopy (FCS) known in recent years as an analysis method that is frequently used particularly in the analysis and the like of molecules derived from organisms and can detect and assay, in almost real time, the physical parameters of protein molecules such as number, sizes, or shapes without undergoing a physical separation step. The present inventors found out that the use of fluorescence labeling by antigen/antibody reaction of an antigen molecule to be detected in the detection and assay of a protein molecule or the like using the FCS as well as the use of a fluorescence-labeled antibody fragment and a non-fluorescence-labeled intact antibody capable of binding to the fluorescence-labeled antibody fragment via an antigen in the fluorescence labeling by the antigen/antibody reaction can allow a significant difference in diffusion rate to arise between the fluorescence-labeled antibody fragment not bonded to the antigen and a complex formed by the antigen/antibody reaction among the fluorescence-labeled antibody fragment,the antigen, and the non-fluorescence-labeled intact antibody. The present inventors found out that according to this method, an antigen can be detected and assayed by using FCS, even in the case of an antigen with a relatively low molecular weight such as an antigenic protein, independently from the shape or molecular weight of the antigen, and thus antigens over a wide scope can be assayed. Based on these findings, the present invention has been completed.
Patent Document 1: Japanese Laid-Open Patent Application No.
Patent Document 2: Japanese Laid-Open Patent Application No.
Patent Document 3: Japanese Laid-Open Patent Application No.
Patent Document 4: Japanese Laid-Open Patent Application No.
Patent Document 5: Japanese Patent No. 3517241 Non-Patent Document 1: J. Infect. Dis. 154: 518-521, 1986 Non-Patent Document 2: Chem. Phys., 4, 390-401, 1974 Non-Patent Document 3: Biopolymers, 13, 1-27, 1974 , . ~
Non-Patent Document 4: Physical Rev. A, 10: 1938-1945, 1974 Non-Patent Document 5: in Topics in Fluorescence Spectroscopy, 1, pp. 337-378, Plenum Press, New York and London, 1991 Non-Patent Document 6: R. Rigler, E. S. Elson (Eds.), Fluorescence Correlation Spectroscopy, Theory and Applications, Springer, Berlin, 2001 Disclosure of the Invention Object to be solved by the Invention [0013]
An object of the present invention is to provide a method of quickly detecting and/or assaying an antigen, which can be applied widely to the detection and/or assay of an antigen such as an antigenic protein,for example,a pathogenic protein(e.g., an abnormal prion) or a harmful protein contained in a food material, whereby the antigen can be detected and/or assayed quickly and accurately by a convenient procedure.
Means to solve the object [0014]
During diligent studies to attain the above object, the present inventors have paid attention to fluorescence correlation spectroscopy (FCS) known in recent years as an analysis method that is frequently used particularly in the analysis and the like of molecules derived from organisms and can detect and assay, in almost real time, the physical parameters of protein molecules such as number, sizes, or shapes without undergoing a physical separation step. The present inventors found out that the use of fluorescence labeling by antigen/antibody reaction of an antigen molecule to be detected in the detection and assay of a protein molecule or the like using the FCS as well as the use of a fluorescence-labeled antibody fragment and a non-fluorescence-labeled intact antibody capable of binding to the fluorescence-labeled antibody fragment via an antigen in the fluorescence labeling by the antigen/antibody reaction can allow a significant difference in diffusion rate to arise between the fluorescence-labeled antibody fragment not bonded to the antigen and a complex formed by the antigen/antibody reaction among the fluorescence-labeled antibody fragment,the antigen, and the non-fluorescence-labeled intact antibody. The present inventors found out that according to this method, an antigen can be detected and assayed by using FCS, even in the case of an antigen with a relatively low molecular weight such as an antigenic protein, independently from the shape or molecular weight of the antigen, and thus antigens over a wide scope can be assayed. Based on these findings, the present invention has been completed.
[0015]
Specifically, the present invention comprises a method of detecting and/or assaying an antigen such as an antigenic protein by using a fluorescence-labeled antibody fragment targeted to an epitope of the antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to form an antigen/antibody complex among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody, and detecting and analyzing the formed antigen/antibody complex by fluorescence correlation spectroscopy. The detection and/or assay method of the present invention can be applied widely to the detection and/or assay of an antigenic protein, for example, a pathogenic protein (e.g., an abnormal prion) or a harmful protein contained in a food material, whereby the antigenic protein can be detected and/or assayed quickly and accurately by a simple procedure.
Specifically, the present invention comprises a method of detecting and/or assaying an antigen such as an antigenic protein by using a fluorescence-labeled antibody fragment targeted to an epitope of the antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to form an antigen/antibody complex among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody, and detecting and analyzing the formed antigen/antibody complex by fluorescence correlation spectroscopy. The detection and/or assay method of the present invention can be applied widely to the detection and/or assay of an antigenic protein, for example, a pathogenic protein (e.g., an abnormal prion) or a harmful protein contained in a food material, whereby the antigenic protein can be detected and/or assayed quickly and accurately by a simple procedure.
[0016]
The function of the present invention will further be described. The present invention comprises mixing a fluorescence-labeled antibody fragment and a intact antibody (or a mixture thereof, i.e., an antigen detection reagent provided by the present invention) each targeted to a different epitope (antigenic determinant) of an antigen such as an antigenic protein(e.g.,a pathogenic protein such as an abnormal prion or a harmful protein such as an allergen protein) with the antigen, performing antigen/antibody reaction thereamong, and assaying the mixture by FCS. In the presence of an antigen such as an antigenic protein in a detection and/or assay sample, the fluorescence-labeled antibody fragment and the non-fluorescence-labeled intact antibody form a complex via the antigen (Figure 1).
The function of the present invention will further be described. The present invention comprises mixing a fluorescence-labeled antibody fragment and a intact antibody (or a mixture thereof, i.e., an antigen detection reagent provided by the present invention) each targeted to a different epitope (antigenic determinant) of an antigen such as an antigenic protein(e.g.,a pathogenic protein such as an abnormal prion or a harmful protein such as an allergen protein) with the antigen, performing antigen/antibody reaction thereamong, and assaying the mixture by FCS. In the presence of an antigen such as an antigenic protein in a detection and/or assay sample, the fluorescence-labeled antibody fragment and the non-fluorescence-labeled intact antibody form a complex via the antigen (Figure 1).
[0017]
To test the influence of a non-fluorescence-labeled intact antibody used in the detection and/or assay of an antigen by FCS on diffusion rate in the Brownian motion of an antigen/antibody complex molecule, a intact antibody and a labeled antibody fragment directly recognizing it were used to perform FCS assay without use of the antigen located in the middle of the complex (Figure 2). As a result of the assay, a significant difference was obtained between the diffusion rate of the labeled antibody fragment alone and the diffusion rate of a labeled antibody fragment/antibody complex (Figure 3). Namely,asa resultof performing antigen/antibody reaction between the f luorescence- labeled antibody fragment recognizing the Fc domain (Figure 2, Epitope C) of the non-fluorescence-labeled intact antibody (Figure 3, Ab) and the non-fluorescence-labeled intact antibody, followed by FCS, as shown in Figure 3, the diffusion time of the labeled antibody fragment alone (Ab(-)) and the diffusion time of the complex (Ab(+)) of the fluorescence-labeled antibody fragment and the non-fluorescence-labeled intact antibody are, theoretically, approximately 600 s and 900 s, respectively, while their measurement values were also approximately 600 s and 950 s , respectively, indicating a significant difference in diffusion rate between the labeled antibody fragment alone and the labeled antibody fragment/antibody complex.
To test the influence of a non-fluorescence-labeled intact antibody used in the detection and/or assay of an antigen by FCS on diffusion rate in the Brownian motion of an antigen/antibody complex molecule, a intact antibody and a labeled antibody fragment directly recognizing it were used to perform FCS assay without use of the antigen located in the middle of the complex (Figure 2). As a result of the assay, a significant difference was obtained between the diffusion rate of the labeled antibody fragment alone and the diffusion rate of a labeled antibody fragment/antibody complex (Figure 3). Namely,asa resultof performing antigen/antibody reaction between the f luorescence- labeled antibody fragment recognizing the Fc domain (Figure 2, Epitope C) of the non-fluorescence-labeled intact antibody (Figure 3, Ab) and the non-fluorescence-labeled intact antibody, followed by FCS, as shown in Figure 3, the diffusion time of the labeled antibody fragment alone (Ab(-)) and the diffusion time of the complex (Ab(+)) of the fluorescence-labeled antibody fragment and the non-fluorescence-labeled intact antibody are, theoretically, approximately 600 s and 900 s, respectively, while their measurement values were also approximately 600 s and 950 s , respectively, indicating a significant difference in diffusion rate between the labeled antibody fragment alone and the labeled antibody fragment/antibody complex.
[0018]
This means that when a complex is formed among the fluorescence-labeled antibody fragment, the antigen, and the non-fluorescence-labeled intact antibody in the presence of the antigen located in the middle of the antigen/antibody complex, a significant difference arises in the diffusion rate of the fluorescence-labeled molecule of them without exception. Thus, it was shown that the use of this combination allows for the detection of an antigen such as an antigenic protein by FCS
assay, independently from the molecular weight of the antigen.
In the method of the present invention, it is preferred to use IgG class monoclonal antibodies as an antibody for preparing the fluorescence-labeled antibody fragment used and as the non-fluorescence-labeled intact antibody.
This means that when a complex is formed among the fluorescence-labeled antibody fragment, the antigen, and the non-fluorescence-labeled intact antibody in the presence of the antigen located in the middle of the antigen/antibody complex, a significant difference arises in the diffusion rate of the fluorescence-labeled molecule of them without exception. Thus, it was shown that the use of this combination allows for the detection of an antigen such as an antigenic protein by FCS
assay, independently from the molecular weight of the antigen.
In the method of the present invention, it is preferred to use IgG class monoclonal antibodies as an antibody for preparing the fluorescence-labeled antibody fragment used and as the non-fluorescence-labeled intact antibody.
[0019]
The experimental examples shown in Figures 2 and 3 complied with the following procedures:
(Materials used):
Alexa Fluor 647 (Zenon One Mouse IgGi Labeling Kit) Fab 647 (Zenon One IgGi Labeling Reagent) Antibody (indicated by Ab in Figure 2) (Zenon One Blocking Reagent (mouse IgG)) (Apparatus for FCS assay):
MF-20 (intermolecular interaction analysis system: Olympus Corp.) (Procedures):
A solution of 10 nM Fab 647 (mouse IgG antibody) alone and a Fab 647 mixture obtained by mixing Fab 647 with 100 nM intact antibody were applied to a 384-well plate (Olympus) blocked with N101 (NOF Corp.), followed by assay with MF20 (Olympus).
The assay was performed by 30 sec. x three measurements at a laser power set to 100 W. The processing software in MF20 was used to derive each parameter including diffusion time.
The experimental examples shown in Figures 2 and 3 complied with the following procedures:
(Materials used):
Alexa Fluor 647 (Zenon One Mouse IgGi Labeling Kit) Fab 647 (Zenon One IgGi Labeling Reagent) Antibody (indicated by Ab in Figure 2) (Zenon One Blocking Reagent (mouse IgG)) (Apparatus for FCS assay):
MF-20 (intermolecular interaction analysis system: Olympus Corp.) (Procedures):
A solution of 10 nM Fab 647 (mouse IgG antibody) alone and a Fab 647 mixture obtained by mixing Fab 647 with 100 nM intact antibody were applied to a 384-well plate (Olympus) blocked with N101 (NOF Corp.), followed by assay with MF20 (Olympus).
The assay was performed by 30 sec. x three measurements at a laser power set to 100 W. The processing software in MF20 was used to derive each parameter including diffusion time.
[0020]
Specifically, the present invention relates to: (1) a method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising using a fluorescence-labeled antibody fragment targeted to an epitope of an antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to form an antigen/antibody complex among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody, and detecting and analyzing the formed antigen/antibody complex by fluorescence correlation spectroscopy; (2) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to (1), wherein the antigen is an antigenic protein; (3) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to (1) or (2), wherein the detection and analysis of the formed antigen/antibody complex by fluorescence correlation spectroscopy are a detection and an analysis of an antigen utilizing discrimination on the basis of a difference in diffusion rate between the fluorescence-labeled antibody fragment and the formed antigen/antibody complex that has been labeled; (4) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of (1) to (3), wherein the quick detection and/or assay of an antigen are detection and/or assay of the presence, concentration, size, or shape of an antigen on the basis of detection and analysis of the formed antigen/antibody complex by fluorescence correlation spectroscopy; and (5) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of (1) to (4), wherein the fluorescence-labeled antibody fragment targeted to an epitope of an antigen is prepared from a monoclonal antibody prepared with an antigen as an immunogen, and the non-fluorescence-labeled intact antibody targeted to another epitope of an antigenic protein is amonoclonal antibodyprepared with an antigen as an immunogen.
Specifically, the present invention relates to: (1) a method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising using a fluorescence-labeled antibody fragment targeted to an epitope of an antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to form an antigen/antibody complex among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody, and detecting and analyzing the formed antigen/antibody complex by fluorescence correlation spectroscopy; (2) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to (1), wherein the antigen is an antigenic protein; (3) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to (1) or (2), wherein the detection and analysis of the formed antigen/antibody complex by fluorescence correlation spectroscopy are a detection and an analysis of an antigen utilizing discrimination on the basis of a difference in diffusion rate between the fluorescence-labeled antibody fragment and the formed antigen/antibody complex that has been labeled; (4) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of (1) to (3), wherein the quick detection and/or assay of an antigen are detection and/or assay of the presence, concentration, size, or shape of an antigen on the basis of detection and analysis of the formed antigen/antibody complex by fluorescence correlation spectroscopy; and (5) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of (1) to (4), wherein the fluorescence-labeled antibody fragment targeted to an epitope of an antigen is prepared from a monoclonal antibody prepared with an antigen as an immunogen, and the non-fluorescence-labeled intact antibody targeted to another epitope of an antigenic protein is amonoclonal antibodyprepared with an antigen as an immunogen.
[0021]
The present invention also relates to: (6) a method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising adding a fluorescence-labeled antibody fragment targeted to an epitope of an antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to a test sample, performing antigen/antibody reaction thereamong, and detecting and analyzing an antigen/antibody complex formed among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody by fluorescence correlation spectroscopy; (7) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to (6), wherein the antigen is an antigenic protein; (8) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to (6) or (7), wherein the detection and/or assay of an antigen by fluorescence correlation spectroscopy are performed without undergoing a step of physically separating the antigen contained in the test sample; (9) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of (6) to (8), wherein the step of adding a fluorescence-labeled antibody fragment targeted to an epitope of the antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to a test sample, the step of performing antigen/antibody reaction among the test sample, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody, and the step of detecting and analyzing the test sample that has undergone the antigen/antibody reaction by fluorescence correlation spectroscopy are performed automatically or semi-automatically; and (10) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of (6) to (9), wherein the test sample is a biological protein sample, and the antigen is a pathogenic protein antigen.
The present invention also relates to: (6) a method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising adding a fluorescence-labeled antibody fragment targeted to an epitope of an antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to a test sample, performing antigen/antibody reaction thereamong, and detecting and analyzing an antigen/antibody complex formed among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody by fluorescence correlation spectroscopy; (7) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to (6), wherein the antigen is an antigenic protein; (8) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to (6) or (7), wherein the detection and/or assay of an antigen by fluorescence correlation spectroscopy are performed without undergoing a step of physically separating the antigen contained in the test sample; (9) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of (6) to (8), wherein the step of adding a fluorescence-labeled antibody fragment targeted to an epitope of the antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to a test sample, the step of performing antigen/antibody reaction among the test sample, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody, and the step of detecting and analyzing the test sample that has undergone the antigen/antibody reaction by fluorescence correlation spectroscopy are performed automatically or semi-automatically; and (10) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of (6) to (9), wherein the test sample is a biological protein sample, and the antigen is a pathogenic protein antigen.
[0022]
The present invention further relates to :(11) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to (10), wherein the pathogenic protein antigen is an abnormal prion; (12) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of (6) to (9), wherein the test sample is a food material, and the antigen is a harmful protein antigen contained in the food material;
(13) a detection reagent for quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising a fluorescence-labeled antibody fragment targeted to an epitope of an antigen to be detected and/or assayed and a non-fluorescence-labeled intact antibody targeted to another epitope of an antigen to be detected and/or assayed; and (14) a kit for quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising the detection reagent according to (12).
Brief Desoription of Drawings [0023]
[Fig. 1]
It is a diagram showing the outline of a method of quickly detecting and/or assaying an antigen by FCS of the present invention.
[Fig. 2]
It is a diagram showing the outline of a test on a difference in diffusion rate between a fluorescence-labeled antibody fragment alone and a complex of the fluorescence-labeled antibody fragment and a intact antibody in order to demonstrate the function of the method of quickly detecting and/or assaying an antigen by FCS of the present invention.
[Fig. 3]
It is a diagram showing a result of the test on a difference in diffusion rate between a fluorescence-labeled antibody fragment alone and a complex of the fluorescence-labeled antibody fragment and a intact antibody in order to demonstrate the function of the method of quickly detecting and/or assaying an antigen by FCS of the present invention.
[Fig.4]
It is a diagram showing the outline of an apparatus for FCS assay used in the present invention.
[Fig. 5]
It is a diagram showing the outline of preparation of a fluorescence-labeled antibody fragment used in the method of quickly detecting and/or assaying an antigen by FCS of the present invention.
[Fig. 6]
It is a diagram showing a result of using a fluorescence-labeled antibody fragment and a intact antibody to test a difference in diffusion time depending on the formation of a complex of the antibody and an antigenic protein in the Examples of the present invention.
Best Mode of Carrying Out the Invention [0024]
A method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy of the present invention comprises using a fluorescence-labeled antibody fragment targeted to an epitope of the antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to form an antigen/antibody complex among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody, and detecting and analyzing the formed antigen/antibody complex by fluorescence correlation spectroscopy (FCS).
The present invention further relates to :(11) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to (10), wherein the pathogenic protein antigen is an abnormal prion; (12) the method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of (6) to (9), wherein the test sample is a food material, and the antigen is a harmful protein antigen contained in the food material;
(13) a detection reagent for quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising a fluorescence-labeled antibody fragment targeted to an epitope of an antigen to be detected and/or assayed and a non-fluorescence-labeled intact antibody targeted to another epitope of an antigen to be detected and/or assayed; and (14) a kit for quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising the detection reagent according to (12).
Brief Desoription of Drawings [0023]
[Fig. 1]
It is a diagram showing the outline of a method of quickly detecting and/or assaying an antigen by FCS of the present invention.
[Fig. 2]
It is a diagram showing the outline of a test on a difference in diffusion rate between a fluorescence-labeled antibody fragment alone and a complex of the fluorescence-labeled antibody fragment and a intact antibody in order to demonstrate the function of the method of quickly detecting and/or assaying an antigen by FCS of the present invention.
[Fig. 3]
It is a diagram showing a result of the test on a difference in diffusion rate between a fluorescence-labeled antibody fragment alone and a complex of the fluorescence-labeled antibody fragment and a intact antibody in order to demonstrate the function of the method of quickly detecting and/or assaying an antigen by FCS of the present invention.
[Fig.4]
It is a diagram showing the outline of an apparatus for FCS assay used in the present invention.
[Fig. 5]
It is a diagram showing the outline of preparation of a fluorescence-labeled antibody fragment used in the method of quickly detecting and/or assaying an antigen by FCS of the present invention.
[Fig. 6]
It is a diagram showing a result of using a fluorescence-labeled antibody fragment and a intact antibody to test a difference in diffusion time depending on the formation of a complex of the antibody and an antigenic protein in the Examples of the present invention.
Best Mode of Carrying Out the Invention [0024]
A method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy of the present invention comprises using a fluorescence-labeled antibody fragment targeted to an epitope of the antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to form an antigen/antibody complex among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody, and detecting and analyzing the formed antigen/antibody complex by fluorescence correlation spectroscopy (FCS).
[0025]
Specif ically, to practice the present invention, the method of quickly detecting and/or assaying an antigen is performed by adding a fluorescence-labeled antibody fragment targeted to an epitope of the antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to a test sample, performing antigen/antibody reaction by mixing the sample supplemented with the antibody, and detecting and analyzing an antigen/antibody complex formed among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody by fluorescence correlation spectroscopy to thereby quickly detect and/or assay the presence, size, concentration, or the like of the antigen in the sample. A treatment procedure in the detection and/or assay by FCS of the present invention is performed by a procedure of merely adding and mixing the sample to a detection reagent comprising the fluorescence-labeled antibody fragment and the non-fluorescence-labeled intact antibody, without undergoing a step of physically separating the antigen contained in the test sample. Therefore, the step of detecting and assaying the antigen can be performed automatically or semi-automatically.
Specif ically, to practice the present invention, the method of quickly detecting and/or assaying an antigen is performed by adding a fluorescence-labeled antibody fragment targeted to an epitope of the antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to a test sample, performing antigen/antibody reaction by mixing the sample supplemented with the antibody, and detecting and analyzing an antigen/antibody complex formed among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody by fluorescence correlation spectroscopy to thereby quickly detect and/or assay the presence, size, concentration, or the like of the antigen in the sample. A treatment procedure in the detection and/or assay by FCS of the present invention is performed by a procedure of merely adding and mixing the sample to a detection reagent comprising the fluorescence-labeled antibody fragment and the non-fluorescence-labeled intact antibody, without undergoing a step of physically separating the antigen contained in the test sample. Therefore, the step of detecting and assaying the antigen can be performed automatically or semi-automatically.
[0026]
(Preparation of anti-protein antibody) In the present invention, to prepare afluorescence-labeled antibody fragment and a non-fluorescence-labeled intact antibody used as a detection reagent, antibodies specifically binding to the antigen are prepared. The antibodies specifically binding to an antigen that are used in the present invention can include polyclonal antibodies and monoclonal antibodies, of which the monoclonal antibodies are more preferable in terms of their specificity. To prepare such antibodies against the antigen, the antigen to be detected is first purified and obtained. The antigen can be prepared by isolation and purification from a donor source using purification means known in the art. Alternatively, if the antigen is an antigenic protein having its amino acid sequence known in the art, the antigenic protein can be obtained by a genetic engineering approach whereby microorganisms, animal cells, or the like are used and allowed to produce the antigenic protein, followed by purification. The antigenic protein can be prepared, when possible, by a chemical peptide synthesis method. The chemical peptide synthesis can adopt synthesis means known in the art. Examples thereof include azide, acid chloride, acid anhydride, mixed anhydride, DCC, active ester, carboimidazole, and oxidation-reduction methods.
(Preparation of anti-protein antibody) In the present invention, to prepare afluorescence-labeled antibody fragment and a non-fluorescence-labeled intact antibody used as a detection reagent, antibodies specifically binding to the antigen are prepared. The antibodies specifically binding to an antigen that are used in the present invention can include polyclonal antibodies and monoclonal antibodies, of which the monoclonal antibodies are more preferable in terms of their specificity. To prepare such antibodies against the antigen, the antigen to be detected is first purified and obtained. The antigen can be prepared by isolation and purification from a donor source using purification means known in the art. Alternatively, if the antigen is an antigenic protein having its amino acid sequence known in the art, the antigenic protein can be obtained by a genetic engineering approach whereby microorganisms, animal cells, or the like are used and allowed to produce the antigenic protein, followed by purification. The antigenic protein can be prepared, when possible, by a chemical peptide synthesis method. The chemical peptide synthesis can adopt synthesis means known in the art. Examples thereof include azide, acid chloride, acid anhydride, mixed anhydride, DCC, active ester, carboimidazole, and oxidation-reduction methods.
[0027]
To prepare antibodies against the antigen, animals or plants are sensitized to the antigen by use of a routine protocol to prepare the antibodies. Any method such as a hybridoma method (Nature 256, 495-497, 1975), trioma method, human B cell hybridoma method (Immunology Today 4, 72, 1983), and EBV-hybridoma method (MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc. , 1985), which provide antibodies produced by cultures of continuous cell lines, can be used, for example, in monoclonal antibody preparation.
To prepare antibodies against the antigen, animals or plants are sensitized to the antigen by use of a routine protocol to prepare the antibodies. Any method such as a hybridoma method (Nature 256, 495-497, 1975), trioma method, human B cell hybridoma method (Immunology Today 4, 72, 1983), and EBV-hybridoma method (MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc. , 1985), which provide antibodies produced by cultures of continuous cell lines, can be used, for example, in monoclonal antibody preparation.
[0028]
To prepare monoclonal antibodies against an antigen such as an antigenic protein, for example, mammals such as rat, mice, or rabbits are sensitized by administering the antigenic protein as an antigen to them. An adjuvant such as a Freund' s complete adjuvant (FCA) or a Freund's incomplete adjuvant (FIA) can be used, if necessary. The immunization is performed mainly by intravenous, hypodermic, or intraperitoneal injection.
Moreover, a time interval between immunizations is not particularly limited, and 1 to 10 immunizations are performed at several-day to several-week intervals. One to sixty days after the final immunization day, antibody-producing cells are collected. The antibody-producing cells include spleen cells, lymph node cells, and peripheral blood cells. To obtain hybridomas, cell fusion is performed between the antibody-producing cells and myeloma cells. Generally obtainable cell lines can be used as the myeloma cells to be fused with the anti.body-producing cells. The cell lines used have drug selectivity and possess the property of being inviable in the unfused form in a HAT selective medium (which contains hypoxanthine, aminopterin, and thymidine) but viable therein only in the form fused with the antibody-producing cells.
To prepare monoclonal antibodies against an antigen such as an antigenic protein, for example, mammals such as rat, mice, or rabbits are sensitized by administering the antigenic protein as an antigen to them. An adjuvant such as a Freund' s complete adjuvant (FCA) or a Freund's incomplete adjuvant (FIA) can be used, if necessary. The immunization is performed mainly by intravenous, hypodermic, or intraperitoneal injection.
Moreover, a time interval between immunizations is not particularly limited, and 1 to 10 immunizations are performed at several-day to several-week intervals. One to sixty days after the final immunization day, antibody-producing cells are collected. The antibody-producing cells include spleen cells, lymph node cells, and peripheral blood cells. To obtain hybridomas, cell fusion is performed between the antibody-producing cells and myeloma cells. Generally obtainable cell lines can be used as the myeloma cells to be fused with the anti.body-producing cells. The cell lines used have drug selectivity and possess the property of being inviable in the unfused form in a HAT selective medium (which contains hypoxanthine, aminopterin, and thymidine) but viable therein only in the form fused with the antibody-producing cells.
[0029]
Hybridomas of interest -are selected from the cells after the cell fusion treatment. A usual cell culture method or ascites formation method can be adopted as a method of collecting monoclonal antibodies from the established hybridomas. When the method of collecting antibodies requires antibody purification, the antibodies can be purified by appropriately selecting methods known in the art such as ammonium sulfate precipitation, ion-exchange chromatography, gel filtration, and affinity chromatography or combining these methods. In the present invention, in addition to the antibodies thus prepared, commercially available already-prepared antibodies, if any, can be used as an antibody against the antigenic protein used in the present invention.
Hybridomas of interest -are selected from the cells after the cell fusion treatment. A usual cell culture method or ascites formation method can be adopted as a method of collecting monoclonal antibodies from the established hybridomas. When the method of collecting antibodies requires antibody purification, the antibodies can be purified by appropriately selecting methods known in the art such as ammonium sulfate precipitation, ion-exchange chromatography, gel filtration, and affinity chromatography or combining these methods. In the present invention, in addition to the antibodies thus prepared, commercially available already-prepared antibodies, if any, can be used as an antibody against the antigenic protein used in the present invention.
[0030]
(Preparation of fluorescence-labeled antibody fragment) In the method of quickly detecting and/or assaying an antigen of the present invention, a fluorescence-labeled antibody fragment prepared from the antigen is used as a detection reagent for performing antigen/antibody reaction with the antigen and detecting the antigen. In the present invention, an antibody that binds to an epitope of the antigen different from that for the non-fluorescence-labeled intact antibody used in the present invention is selected as an antibody used in the preparation of the fluorescence-labeled antibody fragment. To prepare the fluorescence-labeled antibody fragment, a intact antibody against the antigen is fragmented with an enzyme such as pepsin and papain and converted to a monomer by reduction with, for example, 2-mercaptomethylamine or 2-mercaptoethanol, followed by labeling to thereby prepare the fluorescence-labeled antibody fragment. A fluorescentdye is used in the labeling. A fluorescent dye such as fluorescein isothiocyanate (FITC) and Alexa 532 is used.
(Preparation of fluorescence-labeled antibody fragment) In the method of quickly detecting and/or assaying an antigen of the present invention, a fluorescence-labeled antibody fragment prepared from the antigen is used as a detection reagent for performing antigen/antibody reaction with the antigen and detecting the antigen. In the present invention, an antibody that binds to an epitope of the antigen different from that for the non-fluorescence-labeled intact antibody used in the present invention is selected as an antibody used in the preparation of the fluorescence-labeled antibody fragment. To prepare the fluorescence-labeled antibody fragment, a intact antibody against the antigen is fragmented with an enzyme such as pepsin and papain and converted to a monomer by reduction with, for example, 2-mercaptomethylamine or 2-mercaptoethanol, followed by labeling to thereby prepare the fluorescence-labeled antibody fragment. A fluorescentdye is used in the labeling. A fluorescent dye such as fluorescein isothiocyanate (FITC) and Alexa 532 is used.
[0031]
(Detection and assay by FCS) In the method of quickly detecting and/or assaying an antigen of the present invention, the fluorescence-labeled antibody fragment and the non-fluorescence-labeled intact antibody as a detection reagent are added and mixed to a test sample. The test sample that has undergone antigen/antibody reaction is subjected to the detection and/or assay of the antigen by FCS (fluorescence correlation spectroscopy). FCS
is a method whereby the Brownian motions of fluorescent molecules in a solution are used to obtain the physical parameters of the molecules such as "sizes" or "number".
The feature of FCS is that the concentrations or intermolecular interactions of fluorescent molecules contained in a solution can be monitored in almost real time without undergoing a physical separation step. Therefore, a detection system using FCS can avoid a complicated Bound/Free separation step necessary for conventional biomolecule detection systems (e.g., ELISA) performed predominantly. Thus, large amounts of samples can be assayed automatically with high sensitivity in a short time.
A variety of FCS techniques are known, and any method can be used in the present invention unless it hinders the detection and assay of an object to be detected and assayed by the present invention (Protein, Nucleic Acid and Enzyme, Vol. 44, No. 9, 1431-1438, 1999; Bio Industry, April issue, p. 52-59, 2003;
Japanese Laid-Open Patent Application No. 2001-272404; and Japanese Patent No. 3517241).
(Detection and assay by FCS) In the method of quickly detecting and/or assaying an antigen of the present invention, the fluorescence-labeled antibody fragment and the non-fluorescence-labeled intact antibody as a detection reagent are added and mixed to a test sample. The test sample that has undergone antigen/antibody reaction is subjected to the detection and/or assay of the antigen by FCS (fluorescence correlation spectroscopy). FCS
is a method whereby the Brownian motions of fluorescent molecules in a solution are used to obtain the physical parameters of the molecules such as "sizes" or "number".
The feature of FCS is that the concentrations or intermolecular interactions of fluorescent molecules contained in a solution can be monitored in almost real time without undergoing a physical separation step. Therefore, a detection system using FCS can avoid a complicated Bound/Free separation step necessary for conventional biomolecule detection systems (e.g., ELISA) performed predominantly. Thus, large amounts of samples can be assayed automatically with high sensitivity in a short time.
A variety of FCS techniques are known, and any method can be used in the present invention unless it hinders the detection and assay of an object to be detected and assayed by the present invention (Protein, Nucleic Acid and Enzyme, Vol. 44, No. 9, 1431-1438, 1999; Bio Industry, April issue, p. 52-59, 2003;
Japanese Laid-Open Patent Application No. 2001-272404; and Japanese Patent No. 3517241).
[0032]
(Apparatus for FCS assay) The basic structure of an apparatus used in the detection and assay by FCS is shown in Figure 4. To briefly explain it with reference to the figure, Figure 4(A) shows a schematic view of an FCS (fluorescence correlation spectroscopy) apparatus. Excitation light from a laser is directed to a sample solution on a cover glass via a dichroic mirror (DM) and an objective lens. Emitted fluorescence passes through a long pass or band pass filter (F) and is directed to an avalanche photodiode detector (APD) or a photomultiplier ( PMT ) after the removal of background light outside the confocal surface by a confocal pinhole. The signal is further analyzed in a digital correlator. Figure 4(B) shows a magnified schematic view of the observation region. It shows the state where a fluorescent molecule moving in Brownian motion passes through the confocal region narrowed down to the limit by the objective lens. Figure 4(C) shows a correlation curve after fluorescence correlation analysis. The physical parameters of molecules such as "number"
or "sizes" are obtained by analyzing the observed fluctuation of fluorescence intensity by use of formulas.
In the assay by FCS, fluorescence from the exceedingly small region (approximately 400 nm in diameter, approximately 2 m in axis length, less than 10-16 1 in volume) of the sample solution is detected by using a confocal optical system (Figure 4) . In the Examples of the present invention, MF20 manufactured by Olympus Corp. was used as an apparatus for FCS assay. The assay was practiced by a scheme wherein three 30-second measurements were performed at wavelengths of 543 and 633 nm.
(Apparatus for FCS assay) The basic structure of an apparatus used in the detection and assay by FCS is shown in Figure 4. To briefly explain it with reference to the figure, Figure 4(A) shows a schematic view of an FCS (fluorescence correlation spectroscopy) apparatus. Excitation light from a laser is directed to a sample solution on a cover glass via a dichroic mirror (DM) and an objective lens. Emitted fluorescence passes through a long pass or band pass filter (F) and is directed to an avalanche photodiode detector (APD) or a photomultiplier ( PMT ) after the removal of background light outside the confocal surface by a confocal pinhole. The signal is further analyzed in a digital correlator. Figure 4(B) shows a magnified schematic view of the observation region. It shows the state where a fluorescent molecule moving in Brownian motion passes through the confocal region narrowed down to the limit by the objective lens. Figure 4(C) shows a correlation curve after fluorescence correlation analysis. The physical parameters of molecules such as "number"
or "sizes" are obtained by analyzing the observed fluctuation of fluorescence intensity by use of formulas.
In the assay by FCS, fluorescence from the exceedingly small region (approximately 400 nm in diameter, approximately 2 m in axis length, less than 10-16 1 in volume) of the sample solution is detected by using a confocal optical system (Figure 4) . In the Examples of the present invention, MF20 manufactured by Olympus Corp. was used as an apparatus for FCS assay. The assay was practiced by a scheme wherein three 30-second measurements were performed at wavelengths of 543 and 633 nm.
[0033]
(Observed fluctuation of fluorescence intensity) In the assay by FCS, fluorescent molecules go into and out of an observation region according to their Brownian motions because the observation region is an open system. Consequently, the number of the molecules in the observation region varies around a certain value, causing the fluctuation of the number.
The fluctuation of fluorescence intensity attributed to this fluctuation of the number is observed (Protein, Nucleic Acid and Enzyme, Vol. 44, No. 9, 1431-1438, 1999).
(Observed fluctuation of fluorescence intensity) In the assay by FCS, fluorescent molecules go into and out of an observation region according to their Brownian motions because the observation region is an open system. Consequently, the number of the molecules in the observation region varies around a certain value, causing the fluctuation of the number.
The fluctuation of fluorescence intensity attributed to this fluctuation of the number is observed (Protein, Nucleic Acid and Enzyme, Vol. 44, No. 9, 1431-1438, 1999).
[0034]
(Analysis of fluctuation) The observed fluctuation of fluorescence intensity is analyzed by use of formulas (1) to (4) described below to thereby obtain the physical parameters of molecules such as "number"
or "sizes". Specifically, to draw information from the signal of fluctuation, an autocorrelation function is used. The autocorrelation function used in FCS is represented by the formula (1).
Formula 1 [0035]
C~~~ ~ 1+-N 1+r/rD
(Analysis of fluctuation) The observed fluctuation of fluorescence intensity is analyzed by use of formulas (1) to (4) described below to thereby obtain the physical parameters of molecules such as "number"
or "sizes". Specifically, to draw information from the signal of fluctuation, an autocorrelation function is used. The autocorrelation function used in FCS is represented by the formula (1).
Formula 1 [0035]
C~~~ ~ 1+-N 1+r/rD
[0036]
In this context, s represents s=z/w, aratioof the semimajor axis (z) of the observation region to the radius (w) thereof;
tD is called diffusion time (or correlation time) and represents average time when the fluorescent molecules pass through the observation region by diffusion; and N represents the average number of the molecules present in the observation region within a fixed time.
In this context, s represents s=z/w, aratioof the semimajor axis (z) of the observation region to the radius (w) thereof;
tD is called diffusion time (or correlation time) and represents average time when the fluorescent molecules pass through the observation region by diffusion; and N represents the average number of the molecules present in the observation region within a fixed time.
[0037]
The analysis of the fluctuation by the formula (1) gives a curve as shown in Figure 4( C), from which the dif fusion time TD showing the "mobility" of the molecules and the "number" N
of the molecules are obtained. The correlation curve shifts to the right with increases in molecular size, for example, as a result of association of the fluorescent molecules with other molecules, whereas it shifts to the left with decreases in molecular size, for example, as a result of dissociation.
The diffusion time iD obtained by the formula (1) stands in the relationship represented by the formula (2) with the diffusion constant D.
Formula 2 [0038]
Ic. == w 2 / 4D
The analysis of the fluctuation by the formula (1) gives a curve as shown in Figure 4( C), from which the dif fusion time TD showing the "mobility" of the molecules and the "number" N
of the molecules are obtained. The correlation curve shifts to the right with increases in molecular size, for example, as a result of association of the fluorescent molecules with other molecules, whereas it shifts to the left with decreases in molecular size, for example, as a result of dissociation.
The diffusion time iD obtained by the formula (1) stands in the relationship represented by the formula (2) with the diffusion constant D.
Formula 2 [0038]
Ic. == w 2 / 4D
[0039]
Furthermore, the diffusion constant D stands in the relationship represented by the formula (3) with the radius r of the molecule according to the Einstein-Stokes equation based on the assumption that molecules are spherical in shape.
Formula 3 [0040]
D- K----~--~
6:rqr [0041]
In this context, KB, T, and q represent the Boltzmann constant, the absolute temperature, and the viscosity of a solvent, respectively. Thus, the diffusion timeiDcan be linked as shown in the formula (4) to the radius r of the molecule corresponding to the "size" of the molecule according to the formulas (2) and (3).
Formula 4 [0042]
~D oc 1ID cx r [0043]
As described above, the "number" and "sizes" of the molecules present in the observation region can be obtained by analyzing the fluctuation of fluorescence intensity by use of the formulas (1) and (4). Detailed explanation about the fluctuation and the autocorrelation function are described in texts (T. Musha, "World of Fluctuation" Kodansha Bluebacks series, Kodansha Ltd., 1980; D. Eisenberg, et al., "Physical Chemistry With Applications To The Life Sciences", the second volume, Baifukan Co., Ltd., p. 596-600, 1988; and M. Hino, r . .
"Spectrum Analysis", Asakura Publishing Co., Ltd., p. 25-39, 1977).
Furthermore, the diffusion constant D stands in the relationship represented by the formula (3) with the radius r of the molecule according to the Einstein-Stokes equation based on the assumption that molecules are spherical in shape.
Formula 3 [0040]
D- K----~--~
6:rqr [0041]
In this context, KB, T, and q represent the Boltzmann constant, the absolute temperature, and the viscosity of a solvent, respectively. Thus, the diffusion timeiDcan be linked as shown in the formula (4) to the radius r of the molecule corresponding to the "size" of the molecule according to the formulas (2) and (3).
Formula 4 [0042]
~D oc 1ID cx r [0043]
As described above, the "number" and "sizes" of the molecules present in the observation region can be obtained by analyzing the fluctuation of fluorescence intensity by use of the formulas (1) and (4). Detailed explanation about the fluctuation and the autocorrelation function are described in texts (T. Musha, "World of Fluctuation" Kodansha Bluebacks series, Kodansha Ltd., 1980; D. Eisenberg, et al., "Physical Chemistry With Applications To The Life Sciences", the second volume, Baifukan Co., Ltd., p. 596-600, 1988; and M. Hino, r . .
"Spectrum Analysis", Asakura Publishing Co., Ltd., p. 25-39, 1977).
[0044]
(Procedures for using FCS assay and time required) Procedures in the detection and/or assay of an antigenic protein by FCS of the present invention and time required therefor are indicated in comparison to those in a method of detecting and/or assaying an antigenic protein by using a conventional ELISA method.
(1) Comparison of procedures (comparison of convenience) Procedures at each step in the method of quickly detecting and/or assaying an antigenic protein by FCS of the present invention are shown in Table 1.
(Procedures for using FCS assay and time required) Procedures in the detection and/or assay of an antigenic protein by FCS of the present invention and time required therefor are indicated in comparison to those in a method of detecting and/or assaying an antigenic protein by using a conventional ELISA method.
(1) Comparison of procedures (comparison of convenience) Procedures at each step in the method of quickly detecting and/or assaying an antigenic protein by FCS of the present invention are shown in Table 1.
[0045]
[Table 1]
1. Comparison of procedures (comparison of convenience) Step Method using ELISA Present method Immobilization of samples onto Labeling of samples plate (antigen/antibody reaction) with reagent of the Sample Washing of non-specifically present invention treatment step adsorbed samples and liberated (antigen/antibody samples (x3) reaction) Immobilization of enzyme-labeled antibodies onto immobilized samples (antigen/antibody reaction) Signal Washing of non-specifically amplification adsorbed reagents (x5) step Dispense of substrate-coloring solution (enzyme reaction) Dispense of reaction stop solution (inhibition of enzyme reaction) Analysis step Signal assay with plate reader Signal analysis by FCS
[Table 1]
1. Comparison of procedures (comparison of convenience) Step Method using ELISA Present method Immobilization of samples onto Labeling of samples plate (antigen/antibody reaction) with reagent of the Sample Washing of non-specifically present invention treatment step adsorbed samples and liberated (antigen/antibody samples (x3) reaction) Immobilization of enzyme-labeled antibodies onto immobilized samples (antigen/antibody reaction) Signal Washing of non-specifically amplification adsorbed reagents (x5) step Dispense of substrate-coloring solution (enzyme reaction) Dispense of reaction stop solution (inhibition of enzyme reaction) Analysis step Signal assay with plate reader Signal analysis by FCS
[0046]
(2) Comparison of time required (comparison of quickness) Time required for each step in the method of quickly detecting and/or assaying an antigenic protein by FCS of the present invention is shown in Table 2.
(2) Comparison of time required (comparison of quickness) Time required for each step in the method of quickly detecting and/or assaying an antigenic protein by FCS of the present invention is shown in Table 2.
[0047]
[Table 2]
2. Comparison of time required (comparison of quickness) Step Method using ELISA Present method Immobilization of samples onto plate Labeling of samples Sam le 75 minutes with reagent of the p Washing of non-specifically treatment step present invention adsorbed samples and liberated 75 minutes samples 1 minute Immobilization of enzyme-labeled antibodies onto immobilized samples Signal 60 minutes amplification Washing of non-specifically -step adsorbed reagents 1 minute Substrate coloring 30 minutes Signal assay with plate reader Signal analysis by FCS
Analysis step 2 minutes (96 samples) 20 minutes (10-sec measurement/sample x 96 samples) Total 169 minutes 95 minutes [0048]
Hereinafter, the present invention will be described more specifically with reference to the Examples. However, the technical scope of the present invention is not intended to be limited to these illustrations.
Example 1 [0049]
[Detection and assay of antigen (antigenic protein) using FCS]
(Apparatus and materials) (1) Apparatus FCS apparatus Intermolecular interaction analysis system (MF-20, manufactured by Olympus Corp.) (2) Materials Preparation of fluorescence-labeled antibody fragment In this Example, the fluorescence-labeled antibody fragment (Fab'-Alexa 532) of an anti-prion antibody was taken as an example. The outline of preparation of Fab'-Alexa 532 is shown in Figure 5. An anti-PrP antibody solution was equilibrated with a citric acid solution (pH 6.3) by use of a PD-10 column (Pharmacia) and then supplemented (37 C, approximately 30 minutes) with pepsin (1% (w/w)) to prepare F(ab')2. The degree of the digestion was confirmed by HPLC
(column: G300SWXL). Then, the fragment was purified by FPLC
(column: Superdex 200 (16/60)) using 0.1 M phosphate buffer solution (pH 6.3), then concentrated, and stored. It was further reduced ( 37 C, approximately 1. 5 hours) by the addition of 2-mercaptomethylamine (0.01 M) to prepare Fab'.
[Table 2]
2. Comparison of time required (comparison of quickness) Step Method using ELISA Present method Immobilization of samples onto plate Labeling of samples Sam le 75 minutes with reagent of the p Washing of non-specifically treatment step present invention adsorbed samples and liberated 75 minutes samples 1 minute Immobilization of enzyme-labeled antibodies onto immobilized samples Signal 60 minutes amplification Washing of non-specifically -step adsorbed reagents 1 minute Substrate coloring 30 minutes Signal assay with plate reader Signal analysis by FCS
Analysis step 2 minutes (96 samples) 20 minutes (10-sec measurement/sample x 96 samples) Total 169 minutes 95 minutes [0048]
Hereinafter, the present invention will be described more specifically with reference to the Examples. However, the technical scope of the present invention is not intended to be limited to these illustrations.
Example 1 [0049]
[Detection and assay of antigen (antigenic protein) using FCS]
(Apparatus and materials) (1) Apparatus FCS apparatus Intermolecular interaction analysis system (MF-20, manufactured by Olympus Corp.) (2) Materials Preparation of fluorescence-labeled antibody fragment In this Example, the fluorescence-labeled antibody fragment (Fab'-Alexa 532) of an anti-prion antibody was taken as an example. The outline of preparation of Fab'-Alexa 532 is shown in Figure 5. An anti-PrP antibody solution was equilibrated with a citric acid solution (pH 6.3) by use of a PD-10 column (Pharmacia) and then supplemented (37 C, approximately 30 minutes) with pepsin (1% (w/w)) to prepare F(ab')2. The degree of the digestion was confirmed by HPLC
(column: G300SWXL). Then, the fragment was purified by FPLC
(column: Superdex 200 (16/60)) using 0.1 M phosphate buffer solution (pH 6.3), then concentrated, and stored. It was further reduced ( 37 C, approximately 1. 5 hours) by the addition of 2-mercaptomethylamine (0.01 M) to prepare Fab'.
[0050]
The degree of reduction was confirmed by HPLC (column:
G300SWXL). The solution was equilibrated with a citric acid solution (pH 3.5) by use of a PD-10 column (Pharmacia), then immediately supplemented with 2 equivalents of Alexa 532 maleimide (Molecular Probe ), and left overnight at 4 C to perform coupling. Then, the resulting fragment was purified by FPLC
(column: Superdex 200 (16/60)) using 0.05 M phosphate buffer solution (pH 7.8, 0.05% NH3) and cryopreserved at - 80 C . Two types of anti-PrP antibodies (one thus fragmented and labeled, the other used as a intact antibody) and recombinant bovine PrQ (antigen) both were provided by FUJIREBIO INC.
The degree of reduction was confirmed by HPLC (column:
G300SWXL). The solution was equilibrated with a citric acid solution (pH 3.5) by use of a PD-10 column (Pharmacia), then immediately supplemented with 2 equivalents of Alexa 532 maleimide (Molecular Probe ), and left overnight at 4 C to perform coupling. Then, the resulting fragment was purified by FPLC
(column: Superdex 200 (16/60)) using 0.05 M phosphate buffer solution (pH 7.8, 0.05% NH3) and cryopreserved at - 80 C . Two types of anti-PrP antibodies (one thus fragmented and labeled, the other used as a intact antibody) and recombinant bovine PrQ (antigen) both were provided by FUJIREBIO INC.
[0051]
(Experimental procedures of detection and assay of antigenic protein).
The Fab'-Alexa 532 (fluorescence-labeled antibody fragment) (6.86E-10M), the prion protein (antigenic protein) (6.12E-8M), and the intact antibody (anti-bovine recombinant prion antibody) ( 8. 76E-7M) were added in this order to a 384-well plate (Olympus Corp.) blocked with N101 (NOF Corp.) and well mixed with a pipette. The plate was left at 37 C for 1 hour, followed by assay with MF20 (apparatus for FCS assay; Olympus Corp). The assay was performed by three 30- second measurements at a laser power set to 150 ~uW. The processing software in MF20 was used to derive each parameter including diffusion time.
(Experimental procedures of detection and assay of antigenic protein).
The Fab'-Alexa 532 (fluorescence-labeled antibody fragment) (6.86E-10M), the prion protein (antigenic protein) (6.12E-8M), and the intact antibody (anti-bovine recombinant prion antibody) ( 8. 76E-7M) were added in this order to a 384-well plate (Olympus Corp.) blocked with N101 (NOF Corp.) and well mixed with a pipette. The plate was left at 37 C for 1 hour, followed by assay with MF20 (apparatus for FCS assay; Olympus Corp). The assay was performed by three 30- second measurements at a laser power set to 150 ~uW. The processing software in MF20 was used to derive each parameter including diffusion time.
[0052]
(Experimental results) The experimental results are shown in Figure 6. In this Example, the molecular weight of the prion protein is approximately 30 kDa, and therefore, a significant difference in diffusion time might not arise if the intact antibody is not used. Specifically, the theoretical diffusion times of the fluorescence-labeled antibody fragment and a complex (fluorescence-labeled antibody fragment+prion protein) are approximately 600 s and 650 s, respectively. In the experiment as well, the diffusion times of the fluorescence-labeled antibody fragment and the complex (fluorescence-labeled antibody fragment+prion protein) were approximately 600 s and 650 s, respectively, indicating no significant difference (Figure 6). On the other hand, the theoretical diffusion times of the fluorescence-labeled antibody fragment and a complex(fluorescence- labeled antibody fragment+intact antibody+prion protein) are approximately 600 s and 900 s , respectively, and are significantly different.
In the experiment as well, the diffusion times of the fluorescence-labeled antibody fragment and the complex were approximately 600 s and 950 Rs, respectively, close to the theoretical values, indicating a significant difference (Figure 6). Thus, this Example demonstrated that an antigen with a small molecular weight that cannot be detected unless the method of the present invention is used can be detected by using the present method.
Industrial Appliaability [0053]
A method of detecting and/or assaying an antigen by fluorescence correlation spectroscopy (FCS) of the present invention can detect and assay even an antigen with a relatively small molecular weight such as an antigenic protein,for example, a pathogenic protein (e.g., an abnormal prion) or a harmful protein contained in a food material, independently from the shape or molecular weight of the antigen to be detected and/or assayed such as the antigenic protein, and can be used in the detection and/or assay of antigens over a wide scope. Moreover, the detection and/or assay method of the present invention performs the detection and/or assay by FCS. Therefore, it can detect and assay the physical parameters of antigen molecules to be detected such as number, sizes, or shapes in almost real time without undergoing a step of physically separating a sample, and can quickly and accurately detect and/or assay an antigen by a simple procedure.
(Experimental results) The experimental results are shown in Figure 6. In this Example, the molecular weight of the prion protein is approximately 30 kDa, and therefore, a significant difference in diffusion time might not arise if the intact antibody is not used. Specifically, the theoretical diffusion times of the fluorescence-labeled antibody fragment and a complex (fluorescence-labeled antibody fragment+prion protein) are approximately 600 s and 650 s, respectively. In the experiment as well, the diffusion times of the fluorescence-labeled antibody fragment and the complex (fluorescence-labeled antibody fragment+prion protein) were approximately 600 s and 650 s, respectively, indicating no significant difference (Figure 6). On the other hand, the theoretical diffusion times of the fluorescence-labeled antibody fragment and a complex(fluorescence- labeled antibody fragment+intact antibody+prion protein) are approximately 600 s and 900 s , respectively, and are significantly different.
In the experiment as well, the diffusion times of the fluorescence-labeled antibody fragment and the complex were approximately 600 s and 950 Rs, respectively, close to the theoretical values, indicating a significant difference (Figure 6). Thus, this Example demonstrated that an antigen with a small molecular weight that cannot be detected unless the method of the present invention is used can be detected by using the present method.
Industrial Appliaability [0053]
A method of detecting and/or assaying an antigen by fluorescence correlation spectroscopy (FCS) of the present invention can detect and assay even an antigen with a relatively small molecular weight such as an antigenic protein,for example, a pathogenic protein (e.g., an abnormal prion) or a harmful protein contained in a food material, independently from the shape or molecular weight of the antigen to be detected and/or assayed such as the antigenic protein, and can be used in the detection and/or assay of antigens over a wide scope. Moreover, the detection and/or assay method of the present invention performs the detection and/or assay by FCS. Therefore, it can detect and assay the physical parameters of antigen molecules to be detected such as number, sizes, or shapes in almost real time without undergoing a step of physically separating a sample, and can quickly and accurately detect and/or assay an antigen by a simple procedure.
[0054]
~ . ~
Furthermore, in the method of the present invention, which performs the detection and/or assay by FCS , a treatment procedure for the detection and assay by FCS is performed by a procedure of merely mixing a test sample (which contains an antigen) to a detection reagent comprising a fluorescence-labeled antibody fragment and a non-fluorescence-labeled intact antibody and performing antigen/antibody reaction. In addition, the assay results can be monitored in almost real time. Therefore, the method of the present invention is suitable for automatically or semi-automatically performing procedures from the mixing and reaction of the detection reagent with the test sample to the indication of the assay results. Moreover, the method of the present invention comprises a smaller number of steps associated with the analysis procedure than that in methods such as ELISA and western blotting conventionally used in the assay of an antigenic protein such as a prion, and can assay several microliters to several dozen microliters of a sample.
Therefore, it can economically assay large amounts of test samples. Thus, the method of the present invention can be expected to be utilized as practical assay means of an antigenic protein.
~ . ~
Furthermore, in the method of the present invention, which performs the detection and/or assay by FCS , a treatment procedure for the detection and assay by FCS is performed by a procedure of merely mixing a test sample (which contains an antigen) to a detection reagent comprising a fluorescence-labeled antibody fragment and a non-fluorescence-labeled intact antibody and performing antigen/antibody reaction. In addition, the assay results can be monitored in almost real time. Therefore, the method of the present invention is suitable for automatically or semi-automatically performing procedures from the mixing and reaction of the detection reagent with the test sample to the indication of the assay results. Moreover, the method of the present invention comprises a smaller number of steps associated with the analysis procedure than that in methods such as ELISA and western blotting conventionally used in the assay of an antigenic protein such as a prion, and can assay several microliters to several dozen microliters of a sample.
Therefore, it can economically assay large amounts of test samples. Thus, the method of the present invention can be expected to be utilized as practical assay means of an antigenic protein.
Claims (14)
1. A method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising using a fluorescence-labeled antibody fragment targeted to an epitope of an antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to form an antigen/antibody complex among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody, and detecting and analyzing the formed antigen/antibody complex by fluorescence correlation spectroscopy.
2. The method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to claim 1, wherein the antigen is an antigenic protein.
3. The method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to claim 1 or 2, wherein the detection and analysis of the formed antigen/antibody complex by fluorescence correlation spectroscopy are a detection and an analysis of an antigen utilizing discrimination on the basis of a difference in diffusion rate between the fluorescence-labeled antibody fragment and the formed antigen/antibody complex that has been labeled.
4. The method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of claims 1 to 3, wherein the quick detection and/or assay of an antigen are a detection and/or assay of the presence, concentration, size, or shape of an antigen on the basis of detection and analysis of the formed antigen/antibody complex by fluorescence correlation spectroscopy.
5. The method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of claims 1 to 4, wherein the fluorescence-labeled antibody fragment targeted to an epitope of an antigen is prepared from a monoclonal antibody prepared with an antigen as an immunogen, and the non-fluorescence-labeled intact antibody targeted to another epitope of an antigenic protein is a monoclonal antibody prepared with an antigen as an immunogen.
6. A method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising adding a fluorescence-labeled antibody fragment targeted to an epitope of an antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of an antigen to a test sample, performing antigen/antibody reaction thereamong, and detecting and analyzing an antigen/antibody complex formed among the antigen, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody by fluorescence correlation spectroscopy.
7. The method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to claim 6, wherein the antigen is an antigenic protein.
8. The method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to claim 6 or 7, wherein the detection and/or assay of an antigen by fluorescence correlation spectroscopy are performed without undergoing a step of physically separating the antigen contained in the test sample.
9. The method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of claims 6 to 8, wherein the step of adding a fluorescence-labeled antibody fragment targeted to an epitope of the antigen and a non-fluorescence-labeled intact antibody targeted to another epitope of the antigen to a test sample, the step of performing antigen/antibody reaction among the test sample, the fluorescence-labeled antibody fragment, and the non-fluorescence-labeled intact antibody, and the step of detecting and analyzing the test sample that has undergone the antigen/antibody reaction by fluorescence correlation spectroscopy are performed automatically or semi-automatically.
10. The method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of claims 6 to 9, wherein the test sample is a biological protein sample, and the antigen is a pathogenic protein antigen.
11. The method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to claim 10, wherein the pathogenic protein antigen is an abnormal prion.
12. The method of quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy according to any one of claims 6 to 9, wherein the test sample is a food material, and the antigen is a harmful protein antigen contained in the food material.
13. A detection reagent for quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising a fluorescence-labeled antibody fragment targeted to an epitope of an antigen to be detected and/or assayed and a non-fluorescence-labeled intact antibody targeted to another epitope of an antigen to be detected and/or assayed.
14. A kit for quickly detecting and/or assaying an antigen by fluorescence correlation spectroscopy, comprising a detection reagent according to claim 12.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004-166440 | 2004-06-03 | ||
| JP2004166440A JP4338590B2 (en) | 2004-06-03 | 2004-06-03 | Rapid detection and / or measurement of antigen by fluorescence correlation spectroscopy. |
| PCT/JP2005/010043 WO2005119256A1 (en) | 2004-06-03 | 2005-06-01 | Method of quickly detecting and/or assaying antigen by fluorescence correlation spectrometry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2569197A1 true CA2569197A1 (en) | 2005-12-15 |
Family
ID=35463025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002569197A Abandoned CA2569197A1 (en) | 2004-06-03 | 2005-06-01 | Method of quickly detecting and/or assaying antigen by fluorescence correlation spectrometry |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7476545B2 (en) |
| EP (1) | EP1767940A4 (en) |
| JP (1) | JP4338590B2 (en) |
| KR (1) | KR100847349B1 (en) |
| CN (1) | CN1997894A (en) |
| AU (1) | AU2005250710B2 (en) |
| CA (1) | CA2569197A1 (en) |
| TW (1) | TW200609507A (en) |
| WO (1) | WO2005119256A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9040305B2 (en) | 2004-09-28 | 2015-05-26 | Singulex, Inc. | Method of analysis for determining a specific protein in blood samples using fluorescence spectrometry |
| US8685711B2 (en) | 2004-09-28 | 2014-04-01 | Singulex, Inc. | Methods and compositions for highly sensitive detection of molecules |
| CA2621317A1 (en) * | 2005-09-12 | 2007-03-22 | Japan Science And Technology Agency | Method of quickly detecting antigen using fluorescence correlation spectroscopy or fluorescence cross-correlation spectroscopy |
| EP3168618B1 (en) * | 2006-04-04 | 2018-11-21 | Singulex, Inc. | Highly sensitive methods for analysis of troponin |
| JP2010019553A (en) * | 2006-11-02 | 2010-01-28 | Olympus Corp | Specific bonding riaction detecting method of molecule by monomolecular fluorometric analysis |
| JP2009008608A (en) * | 2007-06-29 | 2009-01-15 | Sysmex Corp | Method and kit for determining amount of deoxyribonucleic acid (dna)-binding protein |
| KR101066598B1 (en) * | 2007-12-17 | 2011-09-22 | 한국전자통신연구원 | Method of Multiplex Detecting on Microfluidic Chip |
| US7914734B2 (en) | 2007-12-19 | 2011-03-29 | Singulex, Inc. | Scanning analyzer for single molecule detection and methods of use |
| JP5508808B2 (en) * | 2009-10-15 | 2014-06-04 | オリンパス株式会社 | Image analysis method and image analysis apparatus |
| CN102914654A (en) * | 2011-08-04 | 2013-02-06 | 董方 | Confining liquid and confining method of biochip for detecting various proteins |
| CN103728458B (en) * | 2013-12-31 | 2015-07-22 | 中国农业科学院哈尔滨兽医研究所 | Applications of rabbit encephalitozoon cuniculi spore wall protein SWP1 to preparation of reagent for diagnosing or detecting rabbit encephalitozoon cuniculi infection |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5884394A (en) * | 1993-01-18 | 1994-08-15 | Evotec Biosystems Gmbh | Method and device for assessing the suitability of biopolymers |
| US7241569B2 (en) * | 1993-01-18 | 2007-07-10 | Olympus Corporation | Method and a device for the evaluation of biopolymer fitness |
| DE4301005A1 (en) * | 1993-01-18 | 1994-07-21 | Diagen Inst Molekularbio | Identifying molecules, esp. biopolymers, by fluorescent correlation spectroscopy |
| ATE223058T1 (en) * | 1997-09-19 | 2002-09-15 | Evotec Ag | METHOD FOR MEASURING THE ASSOCIATION OF PARTIAL STRUCTURES OF PATHOLOGICAL PROTEIN DEPOSITS |
| AU5824300A (en) * | 1999-07-05 | 2001-01-22 | Novartis Ag | Sensor platform, apparatus incorporating the platform, and process using the platform |
| EP1211514A4 (en) * | 1999-08-31 | 2005-03-09 | Mitsubishi Chem Corp | Method of analyzing mutual interaction between protein and molecule |
| JP2001272404A (en) * | 2000-03-27 | 2001-10-05 | Olympus Optical Co Ltd | Antigen/antibody reaction by fluorescent correlation spectroscopy |
| WO2002046236A1 (en) * | 2000-12-08 | 2002-06-13 | Fujirebio Inc. | Anti-abnormal prion monoclonal antibody, process for producing the same and immunoassay method with the use thereof |
| CA2442074C (en) * | 2001-03-28 | 2014-07-22 | Heska Corporation | Methods of detecting early renal disease in animals |
| US7045297B2 (en) * | 2001-11-14 | 2006-05-16 | Prion Developmental Laboratories, Inc. | Rapid prion-detection assay |
| US20040191793A1 (en) * | 2002-03-27 | 2004-09-30 | Fumihisa Kitawaki | Fluorescent polarization method, kit used therefor and biosensor |
| JP2005534944A (en) * | 2002-08-01 | 2005-11-17 | センサー テクノロジーズ リミティド ライアビリティー カンパニー | Fluorescence correlation spectrometer |
| CA2496633A1 (en) * | 2002-08-30 | 2004-04-29 | Bf Research Institute, Inc. | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
| JP4274856B2 (en) * | 2003-06-19 | 2009-06-10 | オリンパス株式会社 | Method for detecting reaction between DNA and DNA-binding protein |
-
2004
- 2004-06-03 JP JP2004166440A patent/JP4338590B2/en not_active Expired - Fee Related
-
2005
- 2005-06-01 AU AU2005250710A patent/AU2005250710B2/en not_active Ceased
- 2005-06-01 TW TW094118043A patent/TW200609507A/en unknown
- 2005-06-01 WO PCT/JP2005/010043 patent/WO2005119256A1/en active Application Filing
- 2005-06-01 CN CNA2005800180361A patent/CN1997894A/en active Pending
- 2005-06-01 KR KR1020067027538A patent/KR100847349B1/en not_active IP Right Cessation
- 2005-06-01 CA CA002569197A patent/CA2569197A1/en not_active Abandoned
- 2005-06-01 EP EP05745939A patent/EP1767940A4/en not_active Withdrawn
-
2006
- 2006-12-04 US US11/633,345 patent/US7476545B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005345311A (en) | 2005-12-15 |
| JP4338590B2 (en) | 2009-10-07 |
| WO2005119256A1 (en) | 2005-12-15 |
| EP1767940A1 (en) | 2007-03-28 |
| CN1997894A (en) | 2007-07-11 |
| EP1767940A4 (en) | 2008-08-06 |
| US7476545B2 (en) | 2009-01-13 |
| US20070154950A1 (en) | 2007-07-05 |
| AU2005250710A1 (en) | 2005-12-15 |
| KR20070026671A (en) | 2007-03-08 |
| KR100847349B1 (en) | 2008-07-21 |
| AU2005250710B2 (en) | 2008-10-30 |
| TW200609507A (en) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005250710B2 (en) | Method of quickly detecting and/or assaying antigen by fluorescence correlation spectrometry | |
| CN1325919C (en) | Allergen-microarray assay | |
| JP4977512B2 (en) | Antibody conjugates and methods for immunolabeling | |
| WO2008053822A1 (en) | Method of detecting specific bond reaction of molecule by single molecule fluorometry | |
| JP5155453B2 (en) | Method for quantifying protein leakage from protein-based affinity chromatography resins | |
| US8748355B2 (en) | Antigen detection | |
| Soltermann et al. | Label-free methods for optical in vitro characterization of protein–protein interactions | |
| CN108409841B (en) | Single-domain binding protein for detecting specific allergen IgE and application thereof | |
| EP1939626B1 (en) | Method of quickly detecting antigen using fluorescence correlation spectroscopy or fluorescence cross-correlation spectroscopy | |
| JPH02170053A (en) | Method and device for detecting microorganism | |
| JP2022053276A (en) | Antibody for detection, solid-phase carrier particles, measuring kit for detection target substance, and method for measurement | |
| WO2022065052A1 (en) | Capture antibody, solid-phase carrier, detection antibody, solid-phase carrier particles, and kit and method for measuring detection target substance | |
| US20230107794A1 (en) | Multi Chromophore Fluorescent Dyes with Enhanced Brightness | |
| JP2022053284A (en) | Antibody for capturing, solid-phase carrier, measuring kit for detection target substance, and method for measurement | |
| JP2000266748A (en) | MOUSE IgE MEASUREMENT KIT USING ANTI-MOUSE IgE ANTIBODY AND MEASURING METHOD | |
| JPH0566222A (en) | Material analyzing method | |
| Redegeld et al. | Antibody Detection | |
| KR20150097773A (en) | Immunoassay | |
| CN117491650A (en) | Quantitative detection kit, detection method and application of peripheral blood Hb-Abeta complex | |
| CN117491651A (en) | Quantitative detection kit, detection method and application of Tau complex combined with hemoglobin | |
| JP2008058007A (en) | Measuring method of substance to be inspected using coupling affinity and analysis control method of coupling affinity for measuring substance to be inspected | |
| WO1997011368A1 (en) | Method for the analysis of allergen | |
| Redegeld et al. | B1 Antibody detection | |
| JP2016183966A (en) | Method for measuring target substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |